Healthcare Industry News: metabolic disease
News Release - October 27, 2009
Sorrento Therapeutics Announces the Appointment of Martina Molsbergen as Vice President, Business DevelopmentSAN DIEGO, Oct. 27 -- (Healthcare Sales & Marketing Network) -- Sorrento Therapeutics, Inc. announced today that Martina Molsbergen has joined the Company as Vice President, Business Development. Ms. Molsbergen will focus her efforts on all aspects of business development, including forming alliances based on Sorrento Therapeutics' human monoclonal antibody libraries and technologies.
Ms. Molsbergen is a proven biopharmaceutical business development executive and has negotiated dozens of licensing agreements, collaborations and alliances during her career. Prior to joining Sorrento Therapeutics, Inc., she held similar positions with Crucell NV, where she was responsible for commercializing the PER.C6 manufacturing technology platform, which is based on a fully human cell line for the expression of therapeutic antibodies and other proteins; and with BioWa, Inc., a novel antibody engineering platform company. BioWa, Inc. is a subsidiary of Kyowa Hakko Kirin Co., Ltd.
Dr. Antonius Schuh, Chairman and CEO of Sorrento Therapeutics, commented, "There has been a growing demand from the pharmaceutical and biotechnology industries for antibody-based technologies. Martina brings forth skill sets necessary to capture the value of our human antibody library platform. Her expertise and in-depth knowledge of our industry will be a most valuable asset to Sorrento Therapeutics as we expand our technology platform and product pipeline activities."
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company seeks to construct an antibody library containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets appropriate for antibody therapy.
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), including statements regarding expectations, beliefs or intentions regarding our business, technologies and products strategies or prospects. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the pending matters and transactions being considered by the Company and its parent, QuikByte Software, Inc., may not proceed as contemplated, and by all other matters specified in QuikByte's filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and product candidates. These statements are made based upon current expectations that are subject to risk and uncertainty and information available to QuikByte as of the date of this press release. QuikByte does not undertake to update forward-looking statements in this press release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in QuikByte's filings with the Securities and Exchange Commission, including its most recent periodic report. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
For more information about Sorrento Therapeutics, Inc., visit its web site at www.sorrentotherapeutics.com.
Source: Sorrento Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.